Dawn Toolan

668 total citations
15 papers, 479 citations indexed

About

Dawn Toolan is a scholar working on Molecular Biology, Physiology and Pharmacology. According to data from OpenAlex, Dawn Toolan has authored 15 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Physiology and 4 papers in Pharmacology. Recurrent topics in Dawn Toolan's work include Phosphodiesterase function and regulation (5 papers), Cholinesterase and Neurodegenerative Diseases (4 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). Dawn Toolan is often cited by papers focused on Phosphodiesterase function and regulation (5 papers), Cholinesterase and Neurodegenerative Diseases (4 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). Dawn Toolan collaborates with scholars based in United States and Germany. Dawn Toolan's co-authors include Sarah Jinn, Robert E. Drolet, David J. Stone, Sean M. Smith, Bhavya Voleti, Galya Vassileva, Marija Tadin‐Strapps, Paige E. Cramer, Jyoti Disa and Jacob Marcus and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Bioinformatics and Diabetes.

In The Last Decade

Dawn Toolan

15 papers receiving 474 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dawn Toolan United States 12 234 139 127 92 89 15 479
Paul S. Marinec United States 9 363 1.6× 270 1.9× 75 0.6× 128 1.4× 75 0.8× 10 657
Mari Savolainen Finland 11 245 1.0× 75 0.5× 143 1.1× 26 0.3× 36 0.4× 13 468
Daniel Alvira Spain 13 243 1.0× 124 0.9× 83 0.7× 22 0.2× 62 0.7× 16 514
Sandra Vilotti Italy 13 264 1.1× 101 0.7× 76 0.6× 12 0.1× 55 0.6× 17 508
Bilal Khalil United States 9 307 1.3× 92 0.7× 184 1.4× 33 0.4× 117 1.3× 13 476
Sandra Franco-Iborra Spain 6 341 1.5× 121 0.9× 179 1.4× 25 0.3× 145 1.6× 8 553
Diego E. Hernández Chile 7 364 1.6× 182 1.3× 53 0.4× 26 0.3× 41 0.5× 9 578
Beatrice D’Orsi Ireland 11 332 1.4× 111 0.8× 29 0.2× 30 0.3× 63 0.7× 19 541
С. Н. Пчелина Russia 12 184 0.8× 277 2.0× 244 1.9× 29 0.3× 104 1.2× 76 608
Laura Texidó Spain 7 210 0.9× 165 1.2× 27 0.2× 78 0.8× 24 0.3× 10 466

Countries citing papers authored by Dawn Toolan

Since Specialization
Citations

This map shows the geographic impact of Dawn Toolan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn Toolan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn Toolan more than expected).

Fields of papers citing papers by Dawn Toolan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn Toolan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn Toolan. The network helps show where Dawn Toolan may publish in the future.

Co-authorship network of co-authors of Dawn Toolan

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn Toolan. A scholar is included among the top collaborators of Dawn Toolan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn Toolan. Dawn Toolan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Smith, Sean M., Dawn Toolan, Monika Kandebo, et al.. (2024). Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia. Journal of Pharmacology and Experimental Therapeutics. 392(1). 100047–100047. 1 indexed citations
2.
Jinn, Sarah, Lihang Yao, Monika Kandebo, et al.. (2021). A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiology of Disease. 159. 105507–105507. 14 indexed citations
3.
Toolan, Dawn, Sarah Jinn, Joel B. Schachter, et al.. (2021). Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction. Neurobiology of Aging. 106. 12–25. 11 indexed citations
4.
Jinn, Sarah, Cornelis Blauwendraat, Dawn Toolan, et al.. (2019). Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease. Human Molecular Genetics. 28(19). 3244–3254. 59 indexed citations
5.
Stachel, Shawn J., Melissa S. Egbertson, Jenny Wai, et al.. (2018). Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species. Bioorganic & Medicinal Chemistry Letters. 28(6). 1122–1126. 3 indexed citations
6.
Jinn, Sarah, Robert E. Drolet, Paige E. Cramer, et al.. (2017). TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation. Proceedings of the National Academy of Sciences. 114(9). 2389–2394. 177 indexed citations
7.
Sandhu, Punam, Junghoon Lee, Jeanine Ballard, et al.. (2016). P4‐036: Pharmacokinetics and Pharmacodynamics to Support Clinical Studies of MK‐8719: an O‐Glcnacase Inhibitor for Progressive Supranuclear Palsy. Alzheimer s & Dementia. 12(7S_Part_21). 20 indexed citations
8.
Toolan, Dawn, Monika Kandebo, James C. Hershey, et al.. (2015). The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents. Neuropharmacology. 99. 256–263. 17 indexed citations
9.
Nawrocki, Andrea R., Carlos G. Rodríguez, Dawn Toolan, et al.. (2013). Genetic Deletion and Pharmacological Inhibition of Phosphodiesterase 10A Protects Mice From Diet-Induced Obesity and Insulin Resistance. Diabetes. 63(1). 300–311. 41 indexed citations
10.
Smith, Sean M., Jason M. Uslaner, Christopher D. Cox, et al.. (2012). The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 64. 215–223. 70 indexed citations
11.
Zhang, Xiaohua Douglas, Francesca Santini, Raul Lacson, et al.. (2011). cSSMD: assessing collective activity for addressing off-target effects in genome-scale RNA interference screens. Bioinformatics. 27(20). 2775–2781. 13 indexed citations
12.
Zhao, Weiqin, Dawn Toolan, Robert W. Hepler, et al.. (2011). High Throughput Monitoring of Amyloid-β42 Assembly into Soluble Oligomers Achieved by Sensitive Conformation State-Dependent Immunoassays. Journal of Alzheimer s Disease. 25(4). 655–669. 2 indexed citations
13.
Zhang, Xiaohua Douglas, Raul Lacson, Ruojing Yang, et al.. (2010). The Use of SSMD-Based False Discovery and False Nondiscovery Rates in Genome-Scale RNAi Screens. SLAS DISCOVERY. 15(9). 1123–1131. 21 indexed citations
14.
McCampbell, Alexander, Michael W. Marlatt, Dawn Toolan, et al.. (2010). Induction of Alzheimer’s-like changes in brain of mice expressing mutant APP fed excess methionine. Journal of Neurochemistry. 116(1). 82–92. 19 indexed citations
15.
Hills, Ivory D., M. Katharine Holloway, Hong Zhu, et al.. (2009). A conformational constraint improves a β-secretase inhibitor but for an unexpected reason. Bioorganic & Medicinal Chemistry Letters. 19(17). 4993–4995. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul S. Marinec Breakdown of academic impact, for papers by Mari Savolainen Breakdown of academic impact, for papers by Daniel Alvira Breakdown of academic impact, for papers by Sandra Vilotti Breakdown of academic impact, for papers by Bilal Khalil Breakdown of academic impact, for papers by Sandra Franco-Iborra Breakdown of academic impact, for papers by Diego E. Hernández Breakdown of academic impact, for papers by Beatrice D’Orsi Breakdown of academic impact, for papers by С. Н. Пчелина Breakdown of academic impact, for papers by Laura Texidó
Rankless by CCL
2026